| breast cancer - HR positive | breast cancer - triple negative | |||
| la/mBC - HR-positive - 1st line (L1) | la/mBC - HR positive - L1 - PIK3CA mutant | mBC - Triple negative (TNBC) - 1st Line (L1) | mBC - TNBC - L1 - all population | |
| AKT inhibitor | ||||
| capivasertib based treatment | ||||
| capivasertib plus paclitaxel | BEECH | PAKT ... | PAKT ... | |
| ipatasertib based treatment | ||||
| ipatasertib plus paclitaxel | IPATunity130 | LOTUS | ||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
